A SYSTEMATIC LITERATURE REVIEW (SLR) FOR THE ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA IN BRAZIL, SERBIA AND TU;RKIYE, IN THE CONTEXT OF MULTIPULM HORIZON EU PROJECT
Author(s)
Magda Chatzikou, PhD1, Natalia Trimpouna, MSc1, Fatma Nur Cobanoglu, MSc2, Guilherme Pinheiro, PhD3, Jelena Djekic, PhD4, Neslihan Ozturk, PhD2, Michael Kerr, PhD1.
1Pharmecons Easy Access, York, United Kingdom, 2Ministry of Health of Republic of Türkiye, Ankara, Turkey, 3Fundação Edson Queiroz/Universidade de Fortaleza, Fortaleza, Brazil, 4Institute Za Plucne Bolesti Vojvodine, Novi Sad, Serbia.
1Pharmecons Easy Access, York, United Kingdom, 2Ministry of Health of Republic of Türkiye, Ankara, Turkey, 3Fundação Edson Queiroz/Universidade de Fortaleza, Fortaleza, Brazil, 4Institute Za Plucne Bolesti Vojvodine, Novi Sad, Serbia.
OBJECTIVES: The MULTIPULM project focuses on improving the management of chronic respiratory diseases and multimorbidity through an integrated digital care ecosystem in Brazil, Serbia, and Türkiye. This systematic literature review aimed to identify published evidence on the economic burden of chronic obstructive pulmonary disease (COPD) and asthma in these countries.
METHODS: A systematic literature review was conducted in accordance with PRISMA guidelines. Searches were performed in PubMed, Scopus, Embase, and Google Scholar for studies published between 2016 and 2025. Two independent reviewers conducted title/abstract screening and full-text assessment. Data were categorized by disease and country. Εconomic values were converted to U.S. dollars (USD).
RESULTS: The search identified 351 records. After duplicate removal (n=125), 207 records were excluded and 19 studies were included in the final review. In Brazil, 10 studies were included: six on COPD and four on asthma. Substantial differences were observed between the public and private healthcare sectors. In the public sector, mean COPD hospitalization costs ranged from US$181 in 2016 to US$227 in 2021, while asthma hospitalization costs ranged from US$135 to US$733. COPD intensive care unit (ICU) admissions were associated with higher costs, ranging from US$1,117 to US$1,295. In the private sector, mean COPD hospitalization costs ranged from US$7,648 to US$30,591, increasing to US$14,947-US$53,190 with ICU. Asthma hospitalization costs were US$1,727, rising to US$13,961 for ICU. In Serbia, one study reported COPD hospitalization costs ranging from US$693 to US$799. In Türkiye, eight studies were included: six on COPD and two on asthma. COPD hospitalization costs ranged from US$808.5 to US$1,978 for intensive care. For asthma, annual direct medical costs were estimated at US$4,370, including US$1,155 for hospitalization.
CONCLUSIONS: COPD and asthma impose a substantial economic burden in Brazil, Serbia, and Türkiye. Hospitalization, particularly intensive care, is a major cost driver, highlighting the potential value of improved outpatient care and monitoring.
METHODS: A systematic literature review was conducted in accordance with PRISMA guidelines. Searches were performed in PubMed, Scopus, Embase, and Google Scholar for studies published between 2016 and 2025. Two independent reviewers conducted title/abstract screening and full-text assessment. Data were categorized by disease and country. Εconomic values were converted to U.S. dollars (USD).
RESULTS: The search identified 351 records. After duplicate removal (n=125), 207 records were excluded and 19 studies were included in the final review. In Brazil, 10 studies were included: six on COPD and four on asthma. Substantial differences were observed between the public and private healthcare sectors. In the public sector, mean COPD hospitalization costs ranged from US$181 in 2016 to US$227 in 2021, while asthma hospitalization costs ranged from US$135 to US$733. COPD intensive care unit (ICU) admissions were associated with higher costs, ranging from US$1,117 to US$1,295. In the private sector, mean COPD hospitalization costs ranged from US$7,648 to US$30,591, increasing to US$14,947-US$53,190 with ICU. Asthma hospitalization costs were US$1,727, rising to US$13,961 for ICU. In Serbia, one study reported COPD hospitalization costs ranging from US$693 to US$799. In Türkiye, eight studies were included: six on COPD and two on asthma. COPD hospitalization costs ranged from US$808.5 to US$1,978 for intensive care. For asthma, annual direct medical costs were estimated at US$4,370, including US$1,155 for hospitalization.
CONCLUSIONS: COPD and asthma impose a substantial economic burden in Brazil, Serbia, and Türkiye. Hospitalization, particularly intensive care, is a major cost driver, highlighting the potential value of improved outpatient care and monitoring.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE576
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Topic Subcategory
Value of Information
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)